Integra LifeSciences Holdings (IART) — Analysis Summary
Integra LifeSciences Holdings (IART) has a market cap of $1.45B with year-over-year revenue growth of +1.5%. Net margin stands at -31.6%. The stock trades at a P/E ratio of -2.9.
Key Takeaways
- Revenue changed +1.5% year-over-year
- Net margin of -31.6%
- P/E ratio of -2.9
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, IART posted revenue growth of +1.5% and trades at a P/E of -2.9.
Integra LifeSciences Holdings (IART)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -5.2x — earnings do not cover interest payments
Operating margin at -28.4% — material operating losses
Net margin at -30.1% — significant losses
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
4,427
Headquarters
PRINCETON, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.